Moderna Inc (MRNA)vsNurix Therapeutics Inc (NRIX)
MRNA
Moderna Inc
$214.17
+2.98%
HEALTHCARE · Cap: $87.04B
NRIX
Nurix Therapeutics Inc
$27.26
+2.10%
HEALTHCARE · Cap: $2.67B
Smart Verdict
WallStSmart Research — data-driven comparison
Moderna Inc generates 217% more annual revenue ($2.23B vs $701.94M). NRIX leads profitability with a 42.0% profit margin vs -141.4%. NRIX earns a higher WallStSmart Score of 65/100 (C+).
MRNA
Avoid21
out of 100
Grade: F
NRIX
Buy65
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+69.9%
Fair Value
$134.71
Current Price
$214.16
$79.45 discount
Intrinsic value data unavailable for NRIX.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Conservative balance sheet, low leverage
Attractively priced relative to earnings
Keeps 42 of every $100 in revenue as profit
Strong operational efficiency at 83.1%
Revenue surging 8426.0% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Trading at 12.6x book value
2.1% revenue growth
Weak financial health signals
ROE of -46.6% — below average capital efficiency
0.0% earnings growth
ROE of -61.4% — below average capital efficiency
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : MRNA
The strongest argument for MRNA centers on Market Cap, Debt/Equity.
Bull Case : NRIX
The strongest argument for NRIX centers on P/E Ratio, Profit Margin, Operating Margin. Profitability is solid with margins at 42.0% and operating margin at 83.1%. Revenue growth of 8426.0% demonstrates continued momentum.
Bear Case : MRNA
The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.
Bear Case : NRIX
The primary concerns for NRIX are EPS Growth, Return on Equity, Altman Z-Score.
Key Dynamics to Monitor
MRNA profiles as a turnaround stock while NRIX is a growth play — different risk/reward profiles.
NRIX carries more volatility with a beta of 1.82 — expect wider price swings.
NRIX is growing revenue faster at 8426.0% — sustainability is the question.
NRIX generates stronger free cash flow (614M), providing more financial flexibility.
Bottom Line
NRIX scores higher overall (65/100 vs 21/100), backed by strong 42.0% margins and 8426.0% revenue growth. MRNA offers better value entry with a 69.9% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Moderna Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Nurix Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company is headquartered in San Francisco, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?